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Background:
Measles, mumps, rubella, and varicella were common diseases 
in the United States prior to the introduction of their respective 
vaccines. There are still regions in the world where these diseases 
are highly prevalent.  Even after dramatic reductions in the 
prevalence of measles, mumps, rubella and varicella in the United 
States, there continue to be outbreaks of these diseases, stressing 
the need for ongoing immunization and pre-traveling counseling. 
Most prior studies of seroprevalence for these viral diseases are 
often based on national surveillance data.  It is therefore important 
to get a clearer understanding on the local level of immunity so 
that more focused recommendations can be made for our patient 
population. 
Methods:
Leftover, non-duplicate outpatient serum samples obtained in 
Lehigh Valley Pennsylvania were tested for IgG antibodies using 
commercially available enzyme immunoassays to mumps, measles, 
rubella, and varicella. Samples were collected sequentially, and de-
identified. Five birth cohorts were created and 460 samples were 
collected as follows: <1957 (52), 1957-1966 (109), 1967-1976 
(117), 1977-1988 (121), and 1989-1995 (61). 
Results:
Overall seroprevalence (excluding equivocal results) for measles, 
mumps, rubella, and varicella were (%): 85.8, 82.8, 96.6, and 97.4. 
There was a significant association between seroprevalence and 
birth cohort for measles (p=0.010) and mumps (p=0.037) only. 
Pairwise comparisons of the cohorts found that for measles there 
was a significant difference between the <1957 versus 1967-1976 
(p=0.005) cohort and the <1957 versus 1989-1995 (p=0.001) 
cohort. Additionally, the overall seroprevalence for our study sample 
was significantly different than national seroprevalence results for 
rubella, mumps, and measles. 
Conclusion:
Our study on local seroprevalence showed dramatically lower 
immunity rates to measles and mumps than prior national 
seroprevalence studies have shown. The rates in many of the later 
birth year cohorts were significantly lower than rates reported 
necessary to sustain herd immunity. The results of this study show 
the tremendous value in determining seroprevalence on a local 
basis. We will use these results to alter our approach to assessing 











•  Results of this study will be helpful to guide the approach used when assessing a traveler’s vaccination needs.
•  Data collected will help identify age groups in our region at risk of acquiring vaccine-preventable diseases.
Study Limitations:
•  Our study may be subject to sampling bias due to utilization of a non-probability sampling method.
•  Local immunity rates may have been underestimated as we did not evaluate for cellular immunity through vaccination 
records.
Conclusions
•  Our study, performed in the Lehigh Valley, PA on the local seroprevalence for four vaccine preventable diseases (MMRV) 
showed dramatically lower immunity rates to measles and mumps than previously reported on several national 
seroprevalence surveys. 
•  The immunity rates for many of the later birth cohorts were significantly lower than the rates necessary to sustain herd 
immunity.  
•  The results of this study show the critical value in determining the local seroprevalence. In the presence of ongoing global 
outbreaks, the importance of fostering routine childhood vaccinations and promoting pre travel advice is paramount. 
•  Future studies should be encouraged to document regional and local seroprevalences to vaccine preventable diseases 
throughout the US; to properly advise pre-traveling immunization.
•  There was a statistically significant association between birth cohort and immune status for 
both mumps (p=0.037) and measles (p=0.010).  
•  For measles, the immunity rates of birth cohorts 1967-1976 and 1989-1995 were 
significantly lower when compared to birth cohort <1957 (82.4% vs 98.1%, p=0.005 and 
77.2% vs 98.1%, p=0.001, respectively).
•  More males than females showed humoral immunity to measles in the 1989-1995 cohort, 
92.6% of males vs 63.3% of females (p=0.009). 
•  Our local seroprevalence to measles, mumps, and rubella was significantly different than 
that reported for the national seroprevalence (p<0.001).
•  No statistically significant association between gender and immunity was found for mumps, 
rubella or varicella. 
•  No statistically significant association between birth cohort and immunity status was found 
for rubella or varicella. 
Abstract
Future Directions
•  Creating a seroprevalence study using a probability sampling method and a larger sample size. 
•  Expansion of demographic data collection (country of birth, race/ethnicity, family income, education level and religious/ethical 
beliefs) will help to minimize potential confounders of immunity status.  
•  To include vaccination records of the sample population to evaluate for cellular immunity.








































Percentage of Birth Cohort Immune to Each Disease
(Excluding Equivocal)
Lehigh Valley Health Network, Allentown, PA
Using Locally Derived Seroprevalence Data on Measles, Mumps, Rubella and Varicella by Birth 
Cohort to Determine Risks for Vaccine Preventable Diseases During International Travel
Gisela Rosario, MD; Marcelo Gareca, MD; Hope Kincaid, MPH and Mark Knouse, MD
Table 1: Age by Birth Cohort
  Birth Cohort Mean+SD Range
Less than 1957 72.6±9.7 58-96
1957 to 1966 52.0±2.8 47-57
1967 to 1976 41.8±2.7 37-47
1977 to 1988 31.2±3.5 25-37
1989 to 1995 21.5±2.0 18-25
 
 
Table 2: Gender by Birth Cohort
  Birth Cohort Male N (%) Female N (%) Total N (%)
Less than 1957 27(51.9) 25(48.1) 52(100)
1957 to 1966 51(46.8) 58(53.2) 109(100)
1967 to 1976 59(50.4) 58(49.6) 117(100)
1977 to 1988 58(47.9) 63(52.1) 121(100)
1989 to 1995 28(45.9) 33(54.1) 61(100)
 
 
Table 3: LVHN Overall Seroprevalence by Disease Compared to 
National Seroprevalence (Excluding 1989 - 1955 Cohort)
 Disease LVHN % Immune
US 
% Immune P-value
Rubella1 96.1 89.4 <0.001
Measles3 87.2 93 <0.001
Mumps4 82.4 90 <0.001
 
 
